BioNTech SE (BNTX) announced on Friday that it had negotiated two separate agreements concerning the payment of royalties for its COVID-19 vaccine. The first settlement is with the U.S. National Institutes of Health (NIH) and the second with the University of Pennsylvania (UPenn).
Under these settlements, BioNTech, headquartered in Germany, will pay $791.5 million to the NIH and $467 million to UPenn in order to resolve the lawsuit.
In connection with these agreements, Pfizer (PFE), BioNTech's partner in developing the COVID-19 vaccine, has agreed to reimburse BioNTech for up to $170 million in royalties due to UPenn for sales occurring between 2020 and 2023 as stipulated in the proposed Settlement Agreement.
Furthermore, BioNTech has revised its licensing agreements to include a low single-digit percentage royalty on net sales of licensed products from 2024 onwards.
As of now, BioNTech's shares are trading at $114.25 on the Nasdaq, reflecting a 0.42% increase.
The material has been provided by InstaForex Company - www.instaforex.com
Under these settlements, BioNTech, headquartered in Germany, will pay $791.5 million to the NIH and $467 million to UPenn in order to resolve the lawsuit.
In connection with these agreements, Pfizer (PFE), BioNTech's partner in developing the COVID-19 vaccine, has agreed to reimburse BioNTech for up to $170 million in royalties due to UPenn for sales occurring between 2020 and 2023 as stipulated in the proposed Settlement Agreement.
Furthermore, BioNTech has revised its licensing agreements to include a low single-digit percentage royalty on net sales of licensed products from 2024 onwards.
As of now, BioNTech's shares are trading at $114.25 on the Nasdaq, reflecting a 0.42% increase.
The material has been provided by InstaForex Company - www.instaforex.com